{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:35:38Z","timestamp":1788813338207,"version":"build-2803163510"},"reference-count":50,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Cyprus Ministry of Energy, Commerce, Industry and Tourism\u2013Structural Funds Program","award":["8.1.12.13.2.3.60"],"award-info":[{"award-number":["8.1.12.13.2.3.60"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2022,10,3]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the effectiveness of Neuroaspis plp10 nutritional supplement when added to interferon (IFN)-\u03b2 treatment in patients with relapsing-remitting multiple sclerosis (RRMS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A 30-month phase III multicentre, randomised, double-blind, placebo-controlled trial. Randomisation stratified by centre using a computer-generated procedure with Neuroaspis plp10 versus placebo in 1:1 ratio. The first 6 months were used as both the pre-entry and normalisation period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>3 teaching hospitals in Greece and 1 Neurology Institute in Cyprus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>61 patients with RRMS on IFN-\u03b2 were randomly assigned to receive Neuroaspis plp10 (n=32) or placebo (n=29), 20 mL, orally, once daily, for 30 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>Neuroaspis plp10, a cocktail mixture, containing specific PUFA (12 150 mg) and \u03b3-tocopherol (760 mg) versus virgin olive oil (placebo).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measure<\/jats:title>\n                  <jats:p>The primary end point was the annual relapse rate (ARR) whereas the secondary ones were the rate of sustained progression of disability, as measured by the Expanded Disability Status Scale (EDSS) and the brain T2 and gadolinium-enhancing lesions, at 2 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>For the intention-to-treat analyses Neuroaspis plp10 significantly reduced the ARR by 80%, (RRR, 0.20; 95% CI: 0.09 to 0.45; p=0.0001) and the risk of sustained progression of disability by 73% (HR, 0.27; 95% CI: 0.09 to 0.83; p=0.022) versus placebo, at 2 years. The number of T1 gadolinium-enhancing lesions and the number of new\/enlarged T2-hyperintense lesions were significantly reduced (p=0.01 and p&lt;0.0001, respectively). Both T1-enhancing and new\/enlarging T2-hyperintense lesions were significantly reduced (p=0.05 and p&lt;0.0001, respectively). No significant adverse events were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Neuroaspis plp10 added to IFN-\u03b2 was significantly more effective than IFN-\u03b2 alone in patients with RRMS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN06166891\">ISRCTN06166891<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjno-2022-000334","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T11:34:44Z","timestamp":1667561684000},"page":"e000334","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study"],"prefix":"10.1136","volume":"4","clinical-trial-number":[{"clinical-trial-number":"isrctn06166891","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn06166891","registry":"10.18810\/isrctn"}],"author":[{"given":"Marios C","family":"Pantzaris","sequence":"first","affiliation":[{"name":"Neurology Clinic C, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Bakirtzis","sequence":"additional","affiliation":[{"name":"Department of Neurology Laboratory of Experimental Neurology and Neuroimmunology and the Multiple Sclerosis Center, AHEPA University Hospital, Aristotle University, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Grigoriadis","sequence":"additional","affiliation":[{"name":"Department of Neurology Laboratory of Experimental Neurology and Neuroimmunology and the Multiple Sclerosis Center, AHEPA University Hospital, Aristotle University, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Hadjigeorgiou","sequence":"additional","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia, Cyprus"},{"name":"Department of Neurology, General University Hospital of Larissa, Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthimos","family":"Dardiotis","sequence":"additional","affiliation":[{"name":"Department of Neurology, General University Hospital of Larissa, Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Loucaides","sequence":"additional","affiliation":[{"name":"Neurology Clinic C, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Ntzani","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine (UISM), Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8481-579X","authenticated-orcid":false,"given":"Georgios","family":"Markozannes","sequence":"additional","affiliation":[{"name":"Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savvas","family":"Omorfos","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Valsasina","sequence":"additional","affiliation":[{"name":"Division of Neuroscience, Neuroimaging Research Unit, San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4421-0432","authenticated-orcid":false,"given":"Roberta","family":"Messina","sequence":"additional","affiliation":[{"name":"Division of Neuroscience, Neuroimaging Research Unit, San Raffaele Scientific Institute, Milan, Italy"},{"name":"Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-0019","authenticated-orcid":false,"given":"Paolo","family":"Preziosa","sequence":"additional","affiliation":[{"name":"Division of Neuroscience, Neuroimaging Research Unit, San Raffaele Scientific Institute, Milan, Italy"},{"name":"Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-4320","authenticated-orcid":false,"given":"Maria A","family":"Rocca","sequence":"additional","affiliation":[{"name":"Division of Neuroscience, Neuroimaging Research Unit, San Raffaele Scientific Institute, Milan, Italy"},{"name":"Division of Neuroscience, Universita Vita Salute San Raffaele, Milano, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-7700","authenticated-orcid":false,"given":"Ioannis","family":"Patrikios","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"2025072811401956000_4.2.e000334.1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1602255"},{"key":"2025072811401956000_4.2.e000334.2","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1096\/fasebj.5.13.1916101","article-title":"Dietary fat: exogenous determination of membrane structure and cell function","volume":"5","author":"Clandinin","year":"1991","journal-title":"Faseb J"},{"key":"2025072811401956000_4.2.e000334.3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00232-009-9213-1","article-title":"Red blood cell membrane fluidity in the etiology of multiple sclerosis","volume":"232","author":"Hon","year":"2009","journal-title":"J Membr Biol"},{"key":"2025072811401956000_4.2.e000334.4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.7.3217"},{"key":"2025072811401956000_4.2.e000334.5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0031-6997(24)01472-8","article-title":"The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer","volume":"52","author":"Middleton","year":"2000","journal-title":"Pharmacol Rev"},{"key":"2025072811401956000_4.2.e000334.6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/ajcn\/76.4.703","article-title":"The European perspective on vitamin E: current knowledge and future research","volume":"76","author":"Brigelius-Floh\u00e9","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"2025072811401956000_4.2.e000334.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0753-3322(02)00256-1"},{"key":"2025072811401956000_4.2.e000334.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-5748(00)00013-7"},{"key":"2025072811401956000_4.2.e000334.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198902023200501"},{"key":"2025072811401956000_4.2.e000334.10","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(94)00140-J"},{"key":"2025072811401956000_4.2.e000334.11","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0616"},{"key":"2025072811401956000_4.2.e000334.12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117056"},{"key":"2025072811401956000_4.2.e000334.13","doi-asserted-by":"publisher","DOI":"10.1038\/nri2423"},{"key":"2025072811401956000_4.2.e000334.14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.225"},{"key":"2025072811401956000_4.2.e000334.15","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00077.2002"},{"key":"2025072811401956000_4.2.e000334.16","doi-asserted-by":"publisher","DOI":"10.1038\/nri2294"},{"key":"2025072811401956000_4.2.e000334.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2004.03.005"},{"key":"2025072811401956000_4.2.e000334.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.6.3912"},{"key":"2025072811401956000_4.2.e000334.19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jlb.62.4.438","article-title":"Oral administration of unsaturated fatty acids: effects on human peripheral blood T lymphocyte proliferation","volume":"62","author":"Rossetti","year":"1997","journal-title":"J Leukoc Biol"},{"key":"2025072811401956000_4.2.e000334.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2010.09.012"},{"key":"2025072811401956000_4.2.e000334.21","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.367"},{"key":"2025072811401956000_4.2.e000334.22","doi-asserted-by":"publisher","DOI":"10.1007\/BF02829951"},{"key":"2025072811401956000_4.2.e000334.23","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200700289"},{"key":"2025072811401956000_4.2.e000334.24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2008\/358052","article-title":"Omega-3 fatty acids and PPAR\u03b3 in cancer","volume":"2008","author":"Edwards","year":"2008","journal-title":"PPAR Res"},{"key":"2025072811401956000_4.2.e000334.25","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2702"},{"key":"2025072811401956000_4.2.e000334.26","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.22390"},{"key":"2025072811401956000_4.2.e000334.27","doi-asserted-by":"crossref","unstructured":"McNamara RK . Omega-3 fatty acid deficiency as a risk factor for schizophrenia in: arch Gen psychiatry, 2010.","DOI":"10.1016\/j.schres.2010.12.017"},{"key":"2025072811401956000_4.2.e000334.28","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm223"},{"key":"2025072811401956000_4.2.e000334.29","doi-asserted-by":"crossref","first-page":"C341","DOI":"10.1152\/ajpcell.1995.269.2.C341","article-title":"Arachidonic acid inhibits potassium conductances in cultured rat oligodendrocytes","volume":"269","author":"Soliven","year":"1995","journal-title":"Am J Physiol"},{"key":"2025072811401956000_4.2.e000334.30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/(SICI)1098-1136(199711)21:3<277::AID-GLIA3>3.0.CO;2-2","article-title":"Arachidonic acid inhibits myelin basic protein phosphorylation in cultured oligodendrocytes","volume":"21","author":"Takeda","year":"1997","journal-title":"Glia"},{"key":"2025072811401956000_4.2.e000334.31","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M011692"},{"key":"2025072811401956000_4.2.e000334.32","doi-asserted-by":"publisher","DOI":"10.1054\/plef.2001.0283"},{"key":"2025072811401956000_4.2.e000334.33","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.21537"},{"key":"2025072811401956000_4.2.e000334.34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(03)12512-3","article-title":"Interferons in relapsing remitting multiple sclerosis: a systematic review","volume":"361","author":"Filippini","year":"2003","journal-title":"The Lancet"},{"key":"2025072811401956000_4.2.e000334.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70094-6"},{"key":"2025072811401956000_4.2.e000334.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2003.10.018"},{"key":"2025072811401956000_4.2.e000334.37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/ncpneuro1009","article-title":"Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis","volume":"5","author":"Mehta","year":"2009","journal-title":"Nat Clin Pract Neurol"},{"key":"2025072811401956000_4.2.e000334.38","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"2025072811401956000_4.2.e000334.39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002170"},{"key":"2025072811401956000_4.2.e000334.40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/10543406.2018.1489409","article-title":"Sample size calculations for comparing two groups of count data","volume":"29","author":"Wang","year":"2019","journal-title":"J Biopharm Stat"},{"key":"2025072811401956000_4.2.e000334.41","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2002.10719248"},{"key":"2025072811401956000_4.2.e000334.42","doi-asserted-by":"crossref","first-page":"376S","DOI":"10.1093\/ajcn\/71.1.376S","article-title":"Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders","volume":"71","author":"Mart\u00ednez","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"2025072811401956000_4.2.e000334.43","doi-asserted-by":"publisher","DOI":"10.1177\/009286159703100415"},{"key":"2025072811401956000_4.2.e000334.44","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390304"},{"key":"2025072811401956000_4.2.e000334.45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.4.655"},{"key":"2025072811401956000_4.2.e000334.46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.7.1268"},{"key":"2025072811401956000_4.2.e000334.47","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon \u03b2-1a in relapsing\/remitting multiple sclerosis","volume":"352","author":"Ebers","year":"1998","journal-title":"The Lancet"},{"key":"2025072811401956000_4.2.e000334.48","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/NDT.S114636","article-title":"The use of natalizumab for multiple sclerosis","volume":"13","author":"Brandstadter","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025072811401956000_4.2.e000334.49","first-page":"261","article-title":"Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations","volume":"12","author":"Ayzenberg","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"2025072811401956000_4.2.e000334.50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.clineuro.2018.12.006","article-title":"The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"176","author":"Tamtaji","year":"2019","journal-title":"Clin Neurol Neurosurg"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2022-000334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:40:29Z","timestamp":1753728029000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2022-000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,4]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/bmjno-2022-000334"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2022-000334","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}